17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung role of soluble epoxide hydrolase

American Journal of Respiratory Cell and Molecular Biology

Volumn 43, Issue 5, 2010, Pages 564-575

  Morin, Caroline ^a   Sirois, Marco ^a   Échavé, Vincent ^a   Albadine, Roula ^a   Rousseau, Eric ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Airway inflammation; CPI 17; Eicosanoid; Human bronchi; PPAR

Indexed keywords

12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 17,18 EPOXYEICOSATETRAENOIC ACID; 2 CHLORO 5 NITROBENZANILIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIINFLAMMATORY AGENT; ARACHIDIC ACID; BETA ESCIN; CALCIUM ION; CYCLOOXYGENASE 2; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; I KAPPA B ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOMYOSIN LIGHT CHAIN PHOSPATASE; PHOSPHOPROTEIN; PROTEIN KINASE C POTENTIATED INHIBITOR PROTEIN; REGULATOR PROTEIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 14,15 EPOXY 5,8,11 EICOSATRIENOIC ACID; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; 17,18 EPOXY 5,8,11,14 EICOSATETRAENOIC ACID; 17,18-EPOXY-5,8,11,14-EICOSATETRAENOIC ACID; ARACHIDONIC ACID DERIVATIVE; CALCIUM; DIHOMO GAMMA LINOLENIC ACID; DRUG DERIVATIVE; MYOSIN LIGHT CHAIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PPP1R12A PROTEIN, HUMAN; PPP1R14A PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXPLANT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; BIOLOGICAL MODEL; BRONCHUS; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; LUNG; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PNEUMONIA; SOLUBILITY;

8,11,14-EICOSATRIENOIC ACID; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACIDS; BRONCHI; CALCIUM; CYCLOOXYGENASE 2; EPOXIDE HYDROLASES; HUMANS; LUNG; MODELS, BIOLOGICAL; MYOSIN-LIGHT-CHAIN PHOSPHATASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PNEUMONIA; PPAR GAMMA; PROTEIN KINASE INHIBITORS; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78149253514     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0155OC     Document Type: Article

References (43)

1. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-1875.
2. Jacobs ER, Zeldin DC. The lung HETEs (and EETs) up. Am J Physiol Heart Circ Physiol 2001;280:H1-H10.
3. Nguyen X, Wang MH, Reddy KM, Falck JR, Schwartzman ML. Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol 1999;276:R1691-R1700.
4. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-185.
5. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007;292:C996-C1012.
6. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 1998;284:966-973.
7. Nyby MD, Matsumoto K, Yamamoto K, Abedi K, Eslami P, Hernandez G, Smutko V, Berger ME, Tuck ML. Dietary fish oil prevents vascular dysfunction and oxidative stress in hyperinsulinemic rats. Am J Hypertens 2005;18:213-219.
8. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 2000;41:163-181.
9. Zeldin DC, Foley J, Ma J, Boyle JE, Pascual JM, Moomaw CR, Tomer KB, Steenbergen C, Wu S. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol 1996;50:1111-1117.
10. Zeldin DC, Plitman JD, Kobayashi J, Miller RF, Snapper JR, Falck JR, Szarek JL, Philpot RM, Capdevila JH. The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance. J Clin Invest 1995;95:2150-2160.
11. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET relaxing effects involve BKCa channel activation and CPI-17 dephosphorylation in human bronchi. Am J Respir Cell Mol Biol 2007;36:633-641.
12. Benoit C, Renaudon B, Salvail D, Rousseau E. EETs relax airway smooth muscle via an EpDHF effect: BKCa channel activation and hyperpolarization. Am J Physiol Lung Cell Mol Physiol 2001;280:L965-L973.
13. Node K, Huo Y, Ruan X, Yang Y, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279.
14. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-497. (Pubitemid 29470209)
15. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005;433:413-420.
16. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. 14,15-EET displays anti-inflammatory effects in TNFα-stimulated human bronchi: putative role of CPI-17. Am J Respir Cell Mol Biol 2008;38:192-201.
17. Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, Spector AA. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 2001;276:14867-14874.
18. Liu Y, Zhang Y, Schmelzer K, Lee T-S, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, et al. The anti-inflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 2005;102:16747-16752.
19. Connor WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 2000;71:171S-175S.
20. Simopoulos AP. Essential fatty acids in health and chronic diseases. Forum Nutr 2003;56:67-70.
21. Van Rollins M, Frade PD, Carretero OA. Oxidation of 5,8,11,14,17- eicosapentaenoic acid by hepatic and renal microsomes. Biochim Biophys Acta 1988;966:133-149.
22. Lauterbach B, Barbosa-Sicard E, Wang MH, Honeck H, Kärgel E, Theuer J, Schwartzman ML, Haller H, Luft FC, Gollasch M, et al. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 2002;39:609-613.
23. Schwarz D, Kisselev P, Ericksen SS, Szklarz GD, Chernogolov A, Honeck H, Schunck WH, Roots I. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol 2004;67:1445-1457.
24. Hercule HC, Salanova B, Essin K, Honeck H, Falck JR, Sausbier M, Ruth P, Schunck WH, Luft FC, Gollasch M. The vasodilator 17,18-epoxyeicosatetraenoic acid targets the pore-forming BK alpha channel subunit in rodents. Exp Physiol 2007;92:1067-1076.
25. Morin CS, Sirois M, Echave V, Rizcallah E, Rousseau E. Relaxing effects of 17(18)EpETE on arterial and airway smooth muscles in human lung. Am J Physiol Lung Cell Mol Physiol 2009;296:L130-139.
26. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 1993;13:3301-3310.
27. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869.
28. Shah A, Church MK, Holgate ST. Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy 1995;25:1038-1044.
29. 2+ sensitization in rat ileal longitudinal smooth muscle. Am J Physiol Gastrointest Liver Physiol 2007;293:G699-G710.
30. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 2007;82:42-49.
31. Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006;68:145-151.
32. Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006;36:1494-1504.
33. Sakai H, Chiba Y, Hirano T, Misawa M. Possible involvement of CPI-17 in augmented bronchial smooth muscle contraction in antigen-induced airway hyper-responsive rats. Mol Pharmacol 2006;20:429-447.
34. Léguillette R, Lauzon AM. Molecular mechanics of smooth muscle contractile proteins in airway hyperresponsiveness and asthma. Proc Am Thorac Soc 2008;5:40-46.
35. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008;121:5-10.
36. Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 2009;50 Suppl:S5-56.
37. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 2005;45:311-333.
38. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, Zhu Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 2007;104:9018-9023.
39. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000;87:992-998.
40. Dong X, Liu Y, Du M, Wang Q, Yu CT, Fan X. P38 mitogen-activated protein kinase inhibition attenuates pulmonary inflammatory response in a rat cardiopulmonary bypass model. Eur J Cardiothorac Surg 2006;30:77-84. (Pubitemid 43870152)
41. Escott KJ, Belvisi MG, Birrell MA, Webber SE, Foster ML, Sargent CA. Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat. Br J Pharmacol 2000;131:173-176.
42. 2+ sensitization of bronchial smooth muscle contraction in airway hyperresponsiveness. J Smooth Muscle Res 2004;40:155-167.
43. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, Falck JR, Capdevila JH. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 2005;280:27138-27146.